Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
2.
Clin Res Hepatol Gastroenterol ; 37(6): 642-6, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23796974

RESUMO

BACKGROUND AND OBJECTIVE: To investigate the presence of any possible association between H. pylori density in the stomach and the efficacy of triple (lansoprazole 30 mg b.i.d., clarithromycin 500 mg b.i.d. and amoxicillin 1g b.i.d. for 14 days) and bismuth-containing quadruple (colloidal bismuth subcitrate 300 mg q.i.d., lansoprazole 30 mg b.i.d., tetracycline 500 mg q.i.d. and metronidazole 500 mg t.i.d. for 14 days) eradication therapies. METHODS: Eighty-five cases with H. pylori infection (proved by rapid urease test and histology) were studied. In each case, the density of H. pylori colonization was graded according to the updated Sydney classification. H. pylori eradication was determined via the (14)C-Urea breath test performed 4 weeks after the end of therapy. RESULTS: The eradication rate of H. pylori was 50% (30 out of 60) in the triple therapy and 92% (23 of 25) in the quadruple therapy group. In the triple therapy group, the eradication rate of H. pylori decreased as the initial density of H. pylori increased (density of H. pylori: 1, 58.3%; 2, 54.5%; 3, 52.4%; 4, 38.5%; 5, 33.3%). In two cases with eradication failure after quadruple therapy, the grades of bacterial density were 1 and 3. CONCLUSION: H. pylori density, as assessed by histological grading, may predict the usefulness of triple therapy. The higher the H. pylori density, the less effective triple therapy will be at successful eradication of H. pylori. Quadruple therapy does not seem to be negatively affected by bacterial density.


Assuntos
Anti-Infecciosos/uso terapêutico , Infecções por Helicobacter/tratamento farmacológico , Helicobacter pylori/isolamento & purificação , Inibidores da Bomba de Prótons/uso terapêutico , Estômago/microbiologia , Adolescente , Adulto , Idoso , Amoxicilina/uso terapêutico , Testes Respiratórios , Estudos de Casos e Controles , Claritromicina/uso terapêutico , Quimioterapia Combinada , Dispepsia/microbiologia , Endoscopia Gastrointestinal , Feminino , Humanos , Lansoprazol/uso terapêutico , Masculino , Metronidazol/uso terapêutico , Pessoa de Meia-Idade , Compostos Organometálicos/uso terapêutico , Úlcera Péptica/microbiologia , Estudos Prospectivos , Tetraciclina/uso terapêutico , Resultado do Tratamento , Ureia , Adulto Jovem
3.
Onkologie ; 32(3): 103-6, 2009 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19295248

RESUMO

BACKGROUND: The aim of the study was to determine the impact of the ratio of metastatic to examined lymph nodes (LN) on the survival of early-stage cervical cancer patients. METHODS: A retrospective review was performed of all patients undergoing primary radical hysterectomy and pelvicparaaortic lymphadenectomy for stage I-II cervical cancer at the Ankara Oncology Hospital from 1995 to 2000. Survival was determined by Kaplan-Meier method and differences were assessed by log-rank test. RESULTS: A total of 2,085 LN were examined. Nodal metastasis was found in 22.1% of the patients. Patients with zero involved LN had a 5-year survival of 89.19%, while patients with 1 positive LN and > 1 positive LNs had a 5-year survival of 100 and 76.92%, respectively. The difference in survival among these three groups was not statistically significant. The 5-year survival rates according to the metastatic/examined LN ratio (LNR) were 75, 90, and 89.19% in the groups of patients with LNR >10, 1-10, and 0%, respectively. The difference in survival among these three groups was not statistically significant. CONCLUSIONS: This factor might be helpful for a better prognostic discrimination of patients with metastatic LN. The stratification of node-positive cervical cancer for prognostic and treatment purposes warrants further investigation.


Assuntos
Linfonodos/patologia , Neoplasias do Colo do Útero/mortalidade , Neoplasias do Colo do Útero/patologia , Adulto , Idoso , Ensaios Clínicos como Assunto , Feminino , Alemanha/epidemiologia , Humanos , Incidência , Metástase Linfática , Pessoa de Meia-Idade , Prognóstico , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Análise de Sobrevida , Taxa de Sobrevida , Turquia/epidemiologia , Adulto Jovem
4.
Jpn J Clin Oncol ; 35(10): 607-11, 2005 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16254040

RESUMO

OBJECTIVE: The purpose of this study was to evaluate patient-related parameters that determine ovarian cyst formation in women using tamoxifen for breast cancer. METHODS: A retrospective review of tamoxifen-treated women with breast cancer who were followed up in the outpatient clinic at Ankara Oncology Hospital between January 2002 and December 2004 was performed. Tamoxifen doses and duration, post-treatment menstrual function, adjuvant therapy, ultrasonographic and hormonal [follicle-stimulating hormone and serum estradiol (E(2))] data, details of gynecologic surgical procedure and histopathology were recorded. RESULTS: Twenty-nine of 150 tamoxifen-treated patients (19.3%) had ovarian cysts. Cysts were detected in 28 of 57 pre-menopausal women (49.1%) and 1 of 93 post-menopausal women (1.1%). Patients with ovarian cysts had higher serum E(2) levels compared with patients without cysts (24 versus 345 pg/ml; P < 0.001). Patients with ovarian cysts had <1 year amenorrhoea duration (P < 0.001) compared with the patients without cysts. Adjuvant standard chemotherapy did not have relationship between the development of ovarian cysts. Multivariant analysis showed that cyst development is related to high E(2) levels (P < 0.05). CONCLUSIONS: Patients still having a menstrual cycle during tamoxifen had high risk (58.33%) of developing ovarian cysts. We have described an association between pre-menopausal patients using tamoxifen with high E(2) level and ovarian cyst enlargement.


Assuntos
Antineoplásicos Hormonais/efeitos adversos , Neoplasias da Mama/tratamento farmacológico , Cistos Ovarianos/induzido quimicamente , Tamoxifeno/efeitos adversos , Adulto , Idoso , Idoso de 80 Anos ou mais , Amenorreia/etiologia , Neoplasias da Mama/cirurgia , Estradiol/sangue , Feminino , Hormônio Foliculoestimulante/sangue , Humanos , Pessoa de Meia-Idade , Cistos Ovarianos/sangue , Pós-Menopausa , Pré-Menopausa , Estudos Retrospectivos
5.
Pathol Oncol Res ; 9(2): 100-3, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-12858214

RESUMO

The role of p53 as a prognostic factor is not clear. P53 named as "guardian of the genome" plays an important role in many intracellular regulatory systems, one of which is apoptosis, having an impact on tumor kinetics. A retrospective study was undertaken to assess the relationship of the Nothingham Prognostic Index (NPI) to p53 expression and apoptotic cell counts. To conduct the study, 160 successive cases of infiltrating ductal carcinoma of the breast were included. P53 was assessed on AP-AAP stained sections. Apoptotic cell counting (ACC) was done on the HE stained routine sections in 10 HPFs. Clinical data were derived from the hospital files. Apoptotic cell counts were higher in the p53 positive group but the difference was not significant (p=0.079). P53 positivity was found to be related to the disease-free survival (DFS) (p=0.008). NPI was significantly higher in apoptotic cell containing group (p=0.006). There was a positive linear correlation between ACC and NPI scores (p=0.004). This correlation was not present between apoptosis and disease free survival. P53 expression was found to be related with DFS but not with the NPI which is a score composed of the best prognostic indicators known today. In contrast to this, ACC was found to be closely and linearly associated to the known prognostic factors. This may suggest that the apoptotic cell counts done on routine sections may be used as a part of prognosis assessment in infiltrating ductal carcinoma.


Assuntos
Apoptose , Neoplasias da Mama/metabolismo , Carcinoma Ductal de Mama/metabolismo , Proteína Supressora de Tumor p53/metabolismo , Adulto , Idoso , Idoso de 80 Anos ou mais , Neoplasias da Mama/patologia , Carcinoma Ductal de Mama/patologia , Contagem de Células , Feminino , Humanos , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Prognóstico , Estudos Retrospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA